Genmab — Januar 2018
-
-
Citigroup raises target price on Genmab to DKK 1800, rating buy
-
GENMAB GEN.CO: CITIGROUP RAISES TARGET PRICE TO DKK 1800; RATING BUY - Reuters News
-
Quote fra Bulder den 4/10 1460: Vil lige minde om Citigroups analyse fra august: Amerikanske Citigroup mener, at Genmab-aktiens nuværende pris undervurderer værdien af kræftmidlet Darzalex, skriver Børsen. Citigroup ser derfor mulighed for en pris på 2400 kr. for Genmab-aktien, når det fulde Darzalex-potentiale er indregnet, skriver banken i en analyse i kølvandet på selskabets regnskab for nylig. Banken har dog et kursmål på 1460 kr.
-
Har ikke andre kilder på tidligere taget...
-
Im am sure. It is on reuters this morning 08:26. Here you have it again: GENMAB GEN.CO: CITIGROUP RAISES TARGET PRICE TO DKK 1800; RATING BUY - Reuters News
22-Jan-2018 08:26:01 -
Så er reuters åbenbart ude med gamle nyheder...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind